A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

PG545 (pixatimod) is a novel immunomodulatory agent, which has been demonstrated to stimulate innate immune responses against tumours in preclinical cancer models. This Phase I study investigated the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PG545 monothera...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of cancer Ročník 118; číslo 8; s. 1035 - 1041
Hlavní autoři:	Dredge, Keith, Brennan, Todd V, Hammond, Edward, Lickliter, Jason D, Lin, Liwen, Bampton, Darryn, Handley, Paul, Lankesheer, Fleur, Morrish, Glynn, Yang, Yiping, Brown, Michael P, Millward, Michael
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Nature Publishing Group 01.04.2018
Témata:	Cancer Cell activation Disease control Immune response Immunomodulation Immunomodulators Innate immunity Intravenous administration IP-10 protein Monocyte chemoattractant protein 1 Pharmacodynamics Pharmacokinetics Solid tumors T cell receptors Tumor necrosis factor-α Tumors γ-Interferon
ISSN:	0007-0920, 1532-1827, 1532-1827
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!